-transparent.png){kind=logo}
Tumor imaging by radiopharmaceuticals classified into two modalities; The one is a negative imaging, whereby a tumor is depicted as a non-functional cold spot. The other is a positive imaging on the use of tumor seeking agents. The detectability of the tumor as a cold spot has enhanced by introducing the emission computed tomography. A variety of effort to develop specific tumor seeking agents are in progress, by radio-labeling tumor specific antigen and its abnormal metabolic conditions using cyclotron produced radioactive metabolites as well as radiometal compounds.
Related Publications
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
May 1999,
Thyroid : official journal of the American Thyroid Association,
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
May 1967,
Cancer,
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
July 1976,
Radiology,
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
April 2006,
Nihon rinsho. Japanese journal of clinical medicine,
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
December 1981,
Clinical nuclear medicine,
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
September 1981,
Clinical nuclear medicine,
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
January 1977,
Circulation,
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
July 1979,
Rinsho hoshasen. Clinical radiography,
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
June 1987,
Comprehensive therapy,
Y Ishii, and
T Odori, and
D Hamanaka, and
A Yokoyama, and
K Torizuka
April 1973,
Seminars in nuclear medicine,
